Advisors Capital Management LLC Purchases 8,745 Shares of Bruker Corporation $BRKR

Key Points

• Advisors Capital Management LLC increased its shares in Bruker Corporation by 12% during Q1, totaling 81,425 shares valued at approximately $3.4 million.
• Bruker Corporation reported Q2 earnings per share of $0.32, missing estimates by $0.01, with a revenue of $797.4 million, representing a slight decline compared to the previous year.
• The company announced a quarterly dividend of $0.05 per share, set to be paid on October 3rd, with a current dividend yield of 0.6%.

Advisors Capital Management LLC lifted its position in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 12.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 81,425 shares of the medical research company's stock after purchasing an additional 8,745 shares during the period. Advisors Capital Management LLC owned about 0.05% of Bruker worth $3,399,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in BRKR. Pinnacle Bancorp Inc. bought a new stake in Bruker in the first quarter valued at approximately $29,000. Allworth Financial LP boosted its holdings in Bruker by 92.4% in the first quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after acquiring an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Bruker by 1,354.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock valued at $33,000 after acquiring an additional 745 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC bought a new stake in Bruker in the first quarter valued at approximately $42,000. Finally, MassMutual Private Wealth & Trust FSB boosted its holdings in Bruker by 274.9% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after acquiring an additional 800 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Price Performance

Shares of BRKR opened at $30.91 on Friday. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $72.94. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. The business's 50 day moving average price is $36.02 and its two-hundred day moving average price is $38.98. The firm has a market cap of $4.69 billion, a PE ratio of 59.44, a price-to-earnings-growth ratio of 4.45 and a beta of 1.21.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business had revenue of $797.40 million during the quarter, compared to analyst estimates of $811.17 million. During the same period last year, the firm posted $0.52 earnings per share. Bruker's quarterly revenue was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, equities analysts anticipate that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Tuesday, September 23rd. Bruker's dividend payout ratio is presently 38.46%.

Insider Buying and Selling at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of the company's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the transaction, the director directly owned 18,016 shares of the company's stock, valued at $581,016. This represents a 16.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 27.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BRKR. Wells Fargo & Company reduced their target price on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Tuesday, August 5th. Barclays reduced their target price on Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Monday, August 4th. Jefferies Financial Group set a $60.00 target price on Bruker and gave the company a "buy" rating in a report on Monday, August 4th. Citigroup reduced their target price on Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday, August 4th. Finally, Stifel Nicolaus set a $40.00 price target on Bruker and gave the company a "hold" rating in a research note on Tuesday, August 5th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $51.30.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.